Yeh, Jiunn-TyngJiunn-TyngYehHuang, Chin-ChouChin-ChouHuangLeu, Hsin-BangHsin-BangLeuYin, Wei-HsianWei-HsianYinTseng, Wei-KungWei-KungTsengYEN-WEN WULin, Tsung-HsienTsung-HsienLinYeh, Hung-IHung-IYehChang, Kuan-ChengKuan-ChengChangWang, Ji-HungJi-HungWangCHAU-CHUNG WUChen, Jaw-WenJaw-WenChen2024-03-132024-03-132024-0101609289https://scholars.lib.ntu.edu.tw/handle/123456789/640822Background: Renal dysfunction is common in patients with coronary artery disease. Due to the shared vascular pathogenesis between the two conditions, novel biomarkers such as the fatty acid-binding protein-3 (FABP-3) have been proposed for diagnosis and prognosis prediction. This multicentre prospective cohort study investigates the association between FABP-3 and renal dysfunction. Hypothesis: We hypothesized that higher FABP-3 levels are correlated to worse renal outcome. Methods: Patients with chronic coronary syndrome were classified into three groups based on the initial serum FABP-3 levels. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate the patient's renal function. Renal events were defined as >25% and >50% decline in estimated glomerular filtration rate (eGFR). Cox multivariable regression was employed to delineate the correlation between FABP-3 and renal dysfunction. Results: A total of 1606 subjects were included. During a mean follow-up of 35.9 months, there were 239 patients with eGFR >25% reduction and 60 patients with >50% reduction. In the Kaplan-Meier survival curve and log-rank test, increased levels of FABP-3 were significantly correlated with eGFR >25% reduction (p < .001) and >50% reduction (p < .001). Multivariate Cox regression model revealed that subjects with higher FABP-3 exhibited a greater risk of eGFR >25% reduction (Group 2: hazard ratio [HR] = 2.328, 95% confidence interval [CI] = 1.521-3.562, p < .001; Group 3: HR = 3.054, 95% CI = 1.952-4.776, p < .001) and >50% reduction (Group 3: HR = 4.838, 95% CI = 1.722-13.591, p = .003). Conclusions: Serum FABP-3 may serve as a novel biomarker to predict eGFR decline in patients with chronic coronary syndrome.enchronic coronary syndromeoronary artery diseaseestimated glomerular filtration ratefatty acid-binding protein 3renal function[SDGs]SDG3journal article10.1002/clc.24210382696332-s2.0-85182489470https://api.elsevier.com/content/abstract/scopus_id/85182489470